Overview
Retatrutide is a next-generation triple receptor agonist, simultaneously engaging GLP-1, GIP, and glucagon receptors — one of the most intensively studied peptides in current metabolic and endocrine research.
The Re:Age pen supplies this compound pre-filled at a fixed 40mg concentration, removing the reconstitution step required with a lyophilised vial. Nova Biolabs holds it in UK domestic stock as a brand-partner product.
Key Research Areas
Triple Receptor Pharmacology
Retatrutide's simultaneous engagement of GLP-1, GIP, and glucagon receptors provides a unique research tool for studying combined incretin and glucagon signalling.
Pre-Filled Pen Delivery Research
The Re:Age pen format supplies a fixed, pre-measured dose without a separate reconstitution step, useful where dosing consistency across research sessions matters.
Comparative Agonist Studies
Frequently used alongside GLP-1-only and dual agonists to isolate the contribution of each receptor pathway in metabolic signalling models.
Energy Homeostasis Research
The triple-receptor profile has generated significant research interest in its effects on energy expenditure, thermogenesis signalling, and adipose tissue metabolism.
Product Specifications
| Format | Pre-filled pen, ready to use |
| Content | 40mg Retatrutide |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Do not freeze. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |
Frequently Asked Questions
Commonly Stacked With
Compounds researchers often study alongside this one, and why.
Both feature in Nova’s Premium Bundle — MOTS-c’s mitochondrial signalling research is a common pairing alongside triple-receptor agonist studies.
Paired in the Premium Bundle — NAD+’s role in cellular energy pathways is frequently studied alongside metabolic receptor agonists.
Both feature in Nova’s Elite Bundle — GHRH-analogue research is commonly combined with metabolic receptor studies for broader endocrine-axis coverage.